BioCryst Pharmaceuticals Stock Jumps 13.8%

Shares of the biotech company rise after positive news on its drug pipeline

Mar. 16, 2026 at 6:35pm

Got story updates? Submit your updates here. ›

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) rose 13.8% on Monday, trading as high as $8.30 per share. The company, which is focused on developing treatments for rare and serious diseases, saw increased trading volume as investors reacted to positive developments in its drug pipeline.

Why it matters

BioCryst Pharmaceuticals is a small-cap biotech company that has struggled in recent years, but the jump in its stock price suggests investors see potential in the company's drug development efforts. The stock's performance could indicate growing confidence in the company's ability to bring new treatments to market and generate revenue.

The details

The stock price increase came after BioCryst reported positive data on its experimental drugs. The company's lead drug, Orladeyo, is approved for the treatment of hereditary angioedema (HAE) in the U.S. and Europe. BioCryst is also developing several other drug candidates to treat rare diseases.

  • BioCryst Pharmaceuticals' stock closed at $8.22 on the previous trading day.
  • On Monday, the stock traded as high as $8.30 and closed at $9.3520.

The players

BioCryst Pharmaceuticals, Inc.

A clinical-stage biotechnology company focused on developing treatments for rare and serious diseases.

Orladeyo

BioCryst's lead drug, approved for the treatment of hereditary angioedema (HAE) in the U.S. and Europe.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The jump in BioCryst's stock price suggests investors see potential in the company's drug pipeline, which could indicate growing confidence in the biotech's ability to bring new treatments to market and generate revenue. However, the company still faces significant challenges as a small-cap player in the highly competitive pharmaceutical industry.